Home / Primary antibody / Phospho-NF kappaB p65 (Ser536) Antibody

Phospho-NF kappaB p65 (Ser536) Antibody AF2006

  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
  • Phospho-NF kappaB p65 (Ser536) Antibody
Phospho-NF kappaB p65 (Ser536) Antibody
  • Catalog No.
    AF2006
  • Source
    Rabbit
  • Q04206 UniProt
  • 5970 Gene ID
  • Predicted M.W.
    61kDa
  • Observed M.W.
    65kDa
  • Concentration
    1mg/ml
  • Clonality
    Polyclonal
  • Price/Size
    280$/100ul,350$/200ul
  • Delivery time
    Same day delivery

Browsing history

Datasheet Validation(15) Citations(22) Review Blocking Peptides

1). Wu M et al. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation. Nephrol Dial Transplant 2016 Nov;31(11):1826-1834 (PubMed: 27190325)

Application: WB;   Species: rat;    Sample:None Available;

WB


2). Zeng W et al. Survivin activates NF‑κB p65 via the IKKβ promoter in esophageal squamous cell carcinoma. Mol Med Rep 2016 Feb;13(2):1869-80 (PubMed: 26718331)

Application: WB;   Species: human;    Sample: human;

WB


3). Jiang W et al. Tongxinluo inhibits neointimal formation by regulating the expression and post-translational modification of KLF5 in macrophages. Am J Transl Res 2016 Nov 15;8(11):4778-4790 (PubMed: 27904679)

Application: None Available;   Species:None Available;    Sample:None Available;



4). Yang Z et al. miR-155-dependent regulation of mammalian sterile 20-like kinase 2 (MST2) coordinates inflammation, oxidative stress and proliferation in vascular smooth muscle cells. Biochim Biophys Acta 2015 Jul;1852(7):1477-89 (PubMed: 25892184)

Application: WB(1/400);   Species: mouse;    Sample: mouse;

WB


5). Zhou S et al. AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice. Sci Rep 2017 Feb 22;7:43245 (PubMed: 28225087)

Application: WB(1/500),IHC(1/50);   Species: mouse;    Sample:None Available;

WB IHC


6). Minfei Yang et al. Estrogen receptor β exhibited anti-tumor effects on osteosarcoma cells by regulating integrin, IAP, NFkB/BCL-2 and PI3K/Akt signal pathway. Journal of Bone Oncology 2017 Sep;9:15-20

Application: None Available;   Species:None Available;    Sample:None Available;



7). Zhang X et al. Neuroprotective Effect of Modified Xijiao Dihuang Decoction against Oxygen-Glucose Deprivation and Reoxygenation-Induced Injury in PC12 Cells: Involvement of TLR4-MyD88/NF-κB Signaling Pathway. Evid Based Complement Alternat Med 2017;2017:3848595 (PubMed: 29234386)

Application: None Available;   Species:None Available;    Sample:None Available;



8). Li C et al. TREM2 inhibits inflammatory responses in mouse microglia by suppressing the PI3K/NF-κB signaling. Cell Biol Int 2018 Apr 16 (PubMed: 29663649)

Application: None Available;   Species:None Available;    Sample:None Available;



9). Huang Y et al. LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res 2017 Dec 28;36(1):194 (PubMed: 29282102)

Application: None Available;   Species:None Available;    Sample:None Available;



10). Wu Z et al. EGFR‑associated pathways involved in traditional Chinese medicine (TCM)‑1‑induced cell growth inhibition, autophagy and apoptosis in prostate cancer. Mol Med Rep 2018 Jun;17(6):7875-7885 (PubMed: 29620175)

Application: None Available;   Species:None Available;    Sample:None Available;



11). Li C et al. TREM2 inhibits inflammatory responses in mouse microglia by suppressing the PI3K/NF-κB signaling. Cell Biol Int 2018 Apr 16 (PubMed: 29663649)

Application: None Available;   Species:None Available;    Sample:None Available;



12). Wu Z et al. EGFR‑associated pathways involved in traditional Chinese medicine (TCM)‑1‑induced cell growth inhibition, autophagy and apoptosis in prostate cancer. Mol Med Rep 2018 Jun;17(6):7875-7885 (PubMed: 29620175)

Application: None Available;   Species:None Available;    Sample:None Available;



13). Ding W et al. Therapeutic mild hypothermia improves early outcomes in rats subjected to severe sepsis. Life Sci 2018 Apr 15;199:1-9 (PubMed: 29505782)

Application: None Available;   Species:None Available;    Sample:None Available;



14). Li C et al. TREM2 inhibits inflammatory responses in mouse microglia by suppressing the PI3K/NF-κB signaling. Cell Biol Int 2018 Apr 16 (PubMed: 29663649)

Application: None Available;   Species:None Available;    Sample:None Available;



15). Zhu L et al. miR-199b-5p Regulates Immune-Mediated Allograft Rejection after Lung Transplantation Through the GSK3β and NF-κB Pathways. Inflammation 2018 Aug;41(4):1524-1535 (PubMed: 29779167)

Application: None Available;   Species:None Available;    Sample:None Available;



16). Yang YF et al. Ficolin-A/2, acting as a new regulator of macrophage polarization, mediates the inflammatory response in experimental mouse colitis. Immunology 2017 Aug;151(4):433-450 (PubMed: 28380665)

Application: WB;   Species: mouse;    Sample:None Available;

WB


17). et al. Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats.

Application: None Available;   Species:None Available;    Sample:None Available;



18). Yang M et al. Estrogen receptor β exhibited anti-tumor effects on osteosarcoma cells by regulating integrin, IAP, NF-kB/BCL-2 and PI3K/Akt signal pathway. J Bone Oncol 2017 Sep 28;9:15-20 (PubMed: 29071206)

Application: WB(1/2000);   Species: human;    Sample:None Available;

WB


19). Zhou J et al. Brusatol ameliorates 2, 4, 6-trinitrobenzenesulfonic acid-induced experimental colitis in rats: Involvement of NF-κB pathway and NLRP3 inflammasome. Int Immunopharmacol 2018 Sep 12;64:264-274 (PubMed: 30218953)

Application: None Available;   Species:None Available;    Sample:None Available;



20). Yang Y et al. Black Sesame Seeds Ethanol Extract Ameliorates Hepatic Lipid Accumulation, Oxidative Stress and Insulin Resistance in Fructose-induced Nonalcoholic Fatty Liver Disease. J Agric Food Chem 2018 Sep 24 (PubMed: 30244573)

Application: None Available;   Species:None Available;    Sample:None Available;



21). Wang S et al. E2F2 directly regulates the STAT1 and PI3K/AKT/NF-κB pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts. Arthritis Res Ther 2018 Oct 4;20(1):225 (PubMed: 30286793)

Application: None Available;   Species:None Available;    Sample:None Available;



22). et al. Comparison of anti-inflammatory effects of berberine, and its natural oxidative and reduced derivatives from Rhizoma Coptidis in vitro and in vivo.

Application: None Available;   Species:None Available;    Sample:None Available;



Expand↓

Alternative Names:

Avian reticuloendotheliosis viral (v rel) oncogene homolog A; MGC131774; NF kappa B p65delta3; NFKB3; Nuclear Factor NF Kappa B p65 Subunit; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; OTTHUMP00000233473; OTTHUMP00000233474; OTTHUMP00000233475; OTTHUMP00000233476; OTTHUMP00000233900; p65; p65 NF kappaB; p65 NFkB; relA; TF65_HUMAN; Transcription factor p65; v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)); V rel avian reticuloendotheliosis viral oncogene homolog A; v rel reticuloendotheliosis viral oncogene homolog A (avian); V rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B cells 3, p65;

Applications:

WB 1:500-1:2000 IHC 1:50-1:500 IP 1:100-1:500 IF 1:200, ELISA(peptide) 1:20000-1:40000

Source:

Rabbit

Reactivity:

Human,Mouse,Rat

Clonality:

Polyclonal

Concentration:

1mg/ml

Molecular Weight:

Observed: 65kDa. Predicted: 61kDa.

Phospho-NF kappaB p65 (Ser536) Antibody Western blot analysis of NF kappaB p65 phosphorylation expression in IL-1 treated Raw264.7 whole cell lysates,The lane on the left is treated with the antigen-specific peptide. Western blot analysis of NF kappaB p65 phosphorylation expression in IL-1 treated Raw264.7 whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Phospho-NF kappaB p65 (Ser536) Antibody Representative IHC images of phospho-NF-κB p65 in the medial tibial plateau in AMPKα1α2 conditional double knockout (AMPKα cDKO) mice and their WT littermates 2 weeks post-sham operation and DMM surgery or in mice at 9 months of age. Scale bars = 20 μm. The cellularity of the section was confirmed with haematoxylin staining. Representative IHC images of phospho-NF-κB p65 in the medial tibial plateau in AMPKα1α2 conditional double knockout (AMPKα cDKO) mice and their WT littermates 2 weeks post-sham operation and DMM surgery or in mice at 9 months of age. Scale bars = 20 μm. The cellularity of the section was confirmed with haematoxylin staining.
Phospho-NF kappaB p65 (Ser536) Antibody Western blotting analyses of total NF-κB p65 and phospho-NF-κB p65 in primary murine chondrocytes with or without IL-1β (10 ng/ml) for 24 h. Increased phospho-NF-κB p65 protein expression in chondrocytes from AMPKα cDKO mice compared with their WT littermates was observed. GAPDH served as a loading control. Western blotting analyses of total NF-κB p65 and phospho-NF-κB p65 in primary murine chondrocytes with or without IL-1β (10 ng/ml) for 24 h. Increased phospho-NF-κB p65 protein expression in chondrocytes from AMPKα cDKO mice compared with their WT littermates was observed. GAPDH served as a loading control.
Phospho-NF kappaB p65 (Ser536) Antibody FCN‐A/2, acting as a new regulator of macrophage polarization, mediates the inflammatory response in experimental mouse colitis YF Yang, YD Zhou, JC Hu, FL Luo, Y Xie…  …, 2017  Wiley Online Library FCN‐A/2, acting as a new regulator of macrophage polarization, mediates the inflammatory response in experimental mouse colitis YF Yang, YD Zhou, JC Hu, FL Luo, Y Xie… …, 2017 Wiley Online Library
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining mouse gastric tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining mouse gastric tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining mouse kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining mouse kidney tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining mouse testis tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining mouse testis tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining human heart tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining human heart tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining human brain tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining human brain tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining human liver tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining human liver tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining rat uterine tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining rat uterine tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining rat ovarian tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining rat ovarian tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 at 1/100 staining rat lung tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. AF2006 at 1/100 staining rat lung tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 staining lovo cells by ICC/IF. Cells were fixed with PFA and permeabilized in 0.1% saponin prior to blocking in 10% serum for 45 minutes at 37°C. The primary antibody was diluted 1/400 and incubated with the sample for 1 hour at 37°C. A  Alexa Fluor® 594 conjugated goat polyclonal to rabbit IgG (H+L), diluted 1/600 was used as secondary antibody. AF2006 staining lovo cells by ICC/IF. Cells were fixed with PFA and permeabilized in 0.1% saponin prior to blocking in 10% serum for 45 minutes at 37°C. The primary antibody was diluted 1/400 and incubated with the sample for 1 hour at 37°C. A Alexa Fluor® 594 conjugated goat polyclonal to rabbit IgG (H+L), diluted 1/600 was used as secondary antibody.
Phospho-NF kappaB p65 (Ser536) Antibody AF2006 staining HeLa by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An  Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody. AF2006 staining HeLa by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody.
Peptide Elisa analysis of AF2006 ELISA analysis of AF2006 showing specificity to Phospho-NF kappaB p65 (Ser536) peptide. Peptides concentration: 1ug/ml.
P-peptide: phospho-peptide; N-peptide: non-phospho-peptide.

Purification:

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns.

Specificity:

Phospho-NF- kappaB p65 (Ser536) Antibody detects endogenous levels of NF- kappaB p65 only when phosphorylated at Serine 536.

Immunogen:

A synthesized peptide derived from human NF- kappaB p65 around the phosphorylation site of Serine 536.

Uniprot:

Gene id:

Show more↓

Research Fields:

· Cellular Processes > Cell growth and death > Apoptosis.(View pathway)
· Cellular Processes > Cell growth and death > Cellular senescence.(View pathway)
· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > TNF signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > MAPK signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > Ras signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.(View pathway)
· Environmental Information Processing > Signal transduction > cAMP signaling pathway.(View pathway)

Description:

NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA, or RELB (MIM 604758) to form the NFKB complex. The p50 (NFKB1)/p65 (RELA) heterodimer is the most abundant form of NFKB. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008 or NFKBIB, MIM 604495), which inactivate NFKB by trapping it in the cytoplasm.

Function:

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681).

Subcellular Location:

Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalized with RELA in the nucleus upon TNF-alpha induction.

Post-translational Modifications:

Ubiquitinated, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response.Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes (By similarity).Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity (By similarity). Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity. Phosphorylation at Ser-276 by RPS6KA4 and RPS6KA5 promotes its transactivation and transcriptional activities.Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation at Lys-310 promotes interaction with BRD4. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of Lys-310. Lys-310 is deacetylated by SIRT2.S-nitrosylation of Cys-38 inactivates the enzyme activity.Sulfhydration at Cys-38 mediates the anti-apoptotic activity by promoting the interaction with RPS3 and activating the transcription factor activity.Sumoylation by PIAS3 negatively regulates DNA-bound activated NF-kappa-B.Proteolytically cleaved within a conserved N-terminus region required for base-specific contact with DNA in a CPEN1-mediated manner, and hence inhibits NF-kappa-B transcriptional activity (PubMed:18212740).

Subunit Structure:

Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52 complex. May interact with ETHE1. Binds AES and TLE1. Interacts with TP53BP2. Binds to and is phosphorylated by the activated form of either RPS6KA4 or RPS6KA5. Interacts with ING4 and this interaction may be indirect. Interacts with CARM1, USP48 and UNC5CL. Interacts with IRAK1BP1 (By similarity). Interacts with NFKBID (By similarity). Interacts with NFKBIA. Interacts with GSK3B. Interacts with NFKBIB (By similarity). Interacts with NFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANK repeats) (By similarity). Part of a 70-90 kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA, ELP1 and MAP3K14. Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA. Interacts with HDAC1; the interaction requires non-phosphorylated RELA. Interacts with CBP; the interaction requires phosphorylated RELA. Interacts (phosphorylated at 'Thr-254') with PIN1; the interaction inhibits p65 binding to NFKBIA. Interacts with SOCS1. Interacts with UXT. Interacts with MTDH and PHF11. Interacts with ARRB2. Interacts with human respiratory syncytial virus (HRSV) protein M2-1. Interacts with NFKBIA (when phosphorylated), the interaction is direct; phosphorylated NFKBIA is part of a SCF(BTRC)-like complex lacking CUL1. Interacts with RNF25. Interacts (via C-terminus) with DDX1. Interacts with UFL1 and COMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 (By similarity). Directly interacts with MEN1; this interaction represses NFKB-mediated transactivation. Interacts with AKIP1, which promotes the phosphorylation and nuclear retention of RELA. Interacts (via the RHD) with GFI1; the interaction, after bacterial lipopolysaccharide (LPS) stimulation, inhibits the transcriptional activity by interfering with the DNA-binding activity to target gene promoter DNA. Interacts (when acetylated at Lys-310) with BRD4; leading to activation of the NF-kappa-B pathway. Interacts with MEFV. Interacts with CLOCK (By similarity). Interacts (via N-terminus) with CPEN1; this interaction induces proteolytic cleavage of p65/RELA subunit and inhibition of NF-kappa-B transcriptional activity (PubMed:18212740). Interacts with FOXP3. Interacts with CDK5RAP3; stimulates the interaction of RELA with HDAC1, HDAC2 and HDAC3 thereby inhibiting NF-kappa-B transcriptional activity (PubMed:17785205). Interacts with DHX9; this interaction is direct and activates NF-kappa-B-mediated transcription (PubMed:15355351). Interacts with LRRC25 (PubMed:29044191). Interacts with TBX21 (By similarity). Interacts with KAT2A (By similarity).

Similarity:

the 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Protein BLAST With

Sequence:

        10         20         30         40         50
MDELFPLIFP AEPAQASGPY VEIIEQPKQR GMRFRYKCEG RSAGSIPGER
60 70 80 90 100
STDTTKTHPT IKINGYTGPG TVRISLVTKD PPHRPHPHEL VGKDCRDGFY
110 120 130 140 150
EAELCPDRCI HSFQNLGIQC VKKRDLEQAI SQRIQTNNNP FQVPIEEQRG
160 170 180 190 200
DYDLNAVRLC FQVTVRDPSG RPLRLPPVLS HPIFDNRAPN TAELKICRVN
210 220 230 240 250
RNSGSCLGGD EIFLLCDKVQ KEDIEVYFTG PGWEARGSFS QADVHRQVAI
260 270 280 290 300
VFRTPPYADP SLQAPVRVSM QLRRPSDREL SEPMEFQYLP DTDDRHRIEE
310 320 330 340 350
KRKRTYETFK SIMKKSPFSG PTDPRPPPRR IAVPSRSSAS VPKPAPQPYP
360 370 380 390 400
FTSSLSTINY DEFPTMVFPS GQISQASALA PAPPQVLPQA PAPAPAPAMV
410 420 430 440 450
SALAQAPAPV PVLAPGPPQA VAPPAPKPTQ AGEGTLSEAL LQLQFDDEDL
460 470 480 490 500
GALLGNSTDP AVFTDLASVD NSEFQQLLNQ GIPVAPHTTE PMLMEYPEAI
510 520 530 540 550
TRLVTGAQRP PDPAPAPLGA PGLPNGLLSG DEDFSSIADM DFSALLSQIS

S

Storage Condition and Buffer:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, sodium azide and glycerol.Store at -20 °C.Stable for 12 months from date of receipt.

IMPORTANT: For western blots, incubate membrane with diluted antibody in 5% w/v milk , 1X TBS, 0.1% Tween®20 at 4°C with gentle shaking, overnight.

Customer Reviews and Rankings

  • No comment
Total 0 records, divided into1 pages. First Prev Next Last
My Review  
Username: Anonymous user
E-mail:
Rank:
Content:
Verification code: captcha

Catalog Number :

AF2006-BP

Price/Size :

$200/1mg.
Tips: For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).

Function :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.

Format :

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.The purity is >90%,tested by HPLC and MS.Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions :

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

To Top